Status:
COMPLETED
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
Lead Sponsor:
Facet Biotech
Collaborating Sponsors:
PDL BioPharma, Inc.
Conditions:
Severe Ulcerative Colitis
Eligibility:
All Genders
16-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of visilizumab in patients with severe ulcerative colitis that has failed to respond to steroid therapy. What is visilizumab? Vis...
Detailed Description
PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 16 -70 year olds
- A diagnosis of ulcerative colitis verified by colonoscopy or barium enema performed within 36 months prior to study entry
- Active disease despite ongoing treatment with IV steroids
Exclusion
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT00267306
Start Date
January 1 2004
End Date
December 1 2006
Last Update
March 9 2012
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Inflammatory Bowel Disease Center
Los Angeles, California, United States, 90048
2
University of California, San Francisco
San Francisco, California, United States, 94115
3
Atlanta Gastroenterology Associates
Atlanta, Georgia, United States, 30342
4
Northwestern University
Chicago, Illinois, United States, 60611